XERIS BIOPHARMA HOLDINGS, INC. (XERS) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $63.78M; Long-term Debt, Excluding Current MaturitiesUSD $188.81M; Long-term DebtUSD $252.59M; Long-Term Debt, Maturity, Year OneUSD $33.57M.
- 2026-03-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD $221.22M; Long-term DebtUSD $221.22M; Long-Term Debt, Maturity, Year OneUSD $0.00.
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD $220.34M; Long-term DebtUSD $220.34M; Long-Term Debt, Maturity, Year OneUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD $0.00.
XERIS BIOPHARMA HOLDINGS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD | Debt Instrument, Face Amount USD | Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year USD | Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal after Year Five USD | Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Four USD | Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Three USD | Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Two USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $63.78M | $188.81M | $252.59M | $33.57M | $0.00 | $0.00 | $200.00M | $0.00 | $0.00 | (m) | $233.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $221.22M | $221.22M | $0.00 | $0.00 | $33.57M | $200.00M | $0.00 | $0.00 | (m) | $233.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $220.34M | $220.34M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | $0.00 | $0.00 | $33.57M | $200.00M | $0.00 | $0.00 | (m) | $233.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $219.47M | $219.47M | $0.00 | $0.00 | $33.57M | $200.00M | (m) | (m) | $0.00 | $233.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $218.63M | $218.63M | $0.00 | $0.00 | $33.57M | $200.00M | (m) | (m) | $0.00 | $233.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $11.96M | $217.81M | $229.76M | $0.00 | $0.00 | $33.57M | $200.00M | (m) | (m) | $12.00M | $245.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $15.10M | $217.01M | $232.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | $15.20M | $0.00 | $0.00 | $33.57M | $200.00M | $0.00 | (m) | $248.77M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $15.06M | (m) | $216.23M | $15.20M | $0.00 | $0.00 | $33.57M | (m) | (m) | $0.00 | $248.77M | $231.28M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | $230.48M | $15.20M | $0.00 | $0.00 | $33.57M | (m) | (m) | $0.00 | $248.77M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $229.67M | $15.20M | $0.00 | $0.00 | $33.57M | (m) | (m) | $0.00 | $248.77M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $190.93M | $190.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | $0.00 | $15.20M | $0.00 | $150.00M | $33.57M | $0.00 | (m) | $198.77M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | $190.42M | $0.00 | $15.20M | $0.00 | $150.00M | (m) | (m) | $0.00 | $198.77M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $188.18M | $0.00 | $47.17M | $0.00 | $150.00M | (m) | (m) | $0.00 | $197.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | $187.62M | $0.00 | $47.17M | $0.00 | $150.00M | (m) | (m) | $0.00 | $197.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $187.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | $0.00 | $0.00 | $47.17M | $0.00 | $150.00M | (m) | (m) | $197.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | $138.51M | $0.00 | $0.00 | $47.17M | $0.00 | (m) | (m) | $0.00 | $147.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $138.07M | $0.00 | $0.00 | $47.17M | $0.00 | (m) | (m) | $0.00 | (m) | (m) | $147.18M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $137.64M | $0.00 | $0.00 | $47.17M | $0.00 | (m) | (m) | $0.00 | (m) | (m) | $147.18M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $88.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $90.67M | $0.00 | (m) | $47.17M | $14.50M | $29.00M |
| 2021-09-30 | (m) | (m) | $87.71M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $90.67M | $0.00 | $47.17M | $14.50M | $29.00M | $0.00 |
| 2020-12-31 | (m) | (m) | $87.02M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |